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ABSTRACT
Aims An association between antibody deficiency 
and clozapine use in individuals with schizophrenia 
has recently been reported. We hypothesised that if 
clozapine- associated hypogammaglobulinaemia was 
clinically relevant this would manifest in referral patterns.
Methods Retrospective case note review of patients 
referred and assessed by Immunology Centre for Wales 
(ICW) between January 2005 and July 2018 with 
extraction of clinical and immunological features for 
individuals with diagnosis of schizophrenia- like illness.
Results 1791 adult patients were assessed at ICW 
during this period; 23 patients had a psychiatric 
diagnosis of schizophrenia or schizoaffective disorder. 
Principal indications for referral were findings of low 
calculated globulin and immunoglobulins. Clozapine 
was the single most commonly prescribed antipsychotic 
(17/23), disproportionately increased relative to 
reported use in the general schizophrenia population 
(OR 6.48, 95% CI: 1.79 to 23.5). Clozapine therapy was 
noted in 6/7 (86%) of patients subsequently requiring 
immunoglobulin replacement therapy (IgRT). Marked 
reduction of class- switched memory B cells (CSMB) 
and plasmablasts were observed in clozapine- treated 
individuals relative to healthy age- matched controls. 
Clozapine duration is associated with CSMB decline. One 
patient discontinued clozapine, with gradual recovery of 
IgG levels without use of IgRT.
Conclusions Our findings are consistent with 
enrichment of clozapine- treatment within schizophrenic 
individuals referred for ICW assessment over the last 13 
years. These individuals displayed clinical patterns closely 
resembling the primary immunodeficiency common 
variable immunodeficiency, however appears reversible 
on drug cessation. This has diagnostic, monitoring and 
treatment implications for psychiatry and immunology 
teams and directs prospective studies to address 
causality and the wider implications for this patient 
group.
INTRODUCTION
Schizophrenia is an enduring major psychiatric 
disorder affecting around 1% of the population.1 
In addition to the debilitating psychiatric symp-
toms, it has major psychosocial consequences 
with an unemployment rate of 80%–90% and a 
life expectancy reduced by 10–20 years1 including 
suicide rates of approximately 5%.2 Societal costs 
in England alone are estimated to be £11·8 billion 
per year.3 Clozapine is a dibenzo- diazepine atypical 
antipsychotic and the only licensed medication, for 
approximately 30% of patients with treatment- 
resistant schizophrenia (TRS).1 4 There is increasing 
evidence linking clozapine with pneumonia- related 
admissions5–7 and mortality.8–11 Postulated mecha-
nisms include sialorrhoea, sedation, agranulocytosis 
and aspiration. We recently reported an association 
between clozapine therapy in schizophrenia and 
hypogammaglobulinaemia,12 13 greater than that 
reported following rituximab and methotrexate 
therapy in rheumatoid arthritis.14 To better define 
the clinical and immunological abnormalities asso-
ciated with clozapine use, we performed a retro-
spective case review of patients assessed at the 
Immunology Centre for Wales (ICW).
METHODS
Electronic case records for patients assessed at ICW 
between January 2005 and July 2018 to identify 
all individuals with a concomitant psychiatric diag-
nosis of schizophrenia or schizoaffective disorder. 
Indication for referral, medication and comorbidi-
ties, and immunological testing at initial assessment 
and treatments were extracted using a standardised 
proforma. Recurrent infection history was defined 
as ≥3 distinct antibiotic courses per year or serious 
infection requiring admission, as in the wider 
literature.15
All testing was performed in the United Kingdom 
Accreditation Service- accredited Medical Biochem-
istry & Immunology Laboratory at the University 
Hospital of Wales. Immunoglobulin levels (IgG, IgA 
and IgM) were assayed by nephelometry (Siemens 
BN2 Nephelometer; Siemens), serum electropho-
resis (Sebia Capillarys 2; Sebia, Norcross, Georgia, 
USA) and, where appropriate, serum immu-
nofixation performed (Sebia Hydrasys; Sebia). 
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Antibody titres against Haemophilus influenzaeand Strepto-
coccus pneumoniae capsular polysaccharide and tetanus toxoid 
were determined by ELISA (The Binding Site, Birmingham, 
UK). Flow cytometry was performed using Beckman Coulter 
FC500 analyser. Lymphocyte phenotypes were analysed using 
Beckman Coulter Cyto- stat Tetrachrome reagents (CD45- FITC/
CD4- RD1/CD8- ECD/CD3- PC5 and CD45- FITC/CD56- RD1/
CD10- ECD/CD3- PC5), Flow- Count Fluorospheres and versa-
lyse lysis solution. B- cell phenotyping was performed as previ-
ously described16 using the following antibodies: CD19- PE/
Cy7 (Beckman Coulter), CD27- FITC (Serotec), CD21- PE (BD 
Pharmingen), CD38- FITC (Beckman Coulter), IgM Alexa- Flour 
647 (Jackson ImmunoResearch), IgD- PE (Southern Biotech). 
Common variable immunodeficiency (CVID) and age- matched 
healthy controls were analysed as part of an anonymous sample 
exchange scheme run jointly with King’s College London. Refer-
ence ranges are provided within the text. Individual clinical, 
immune and treatment data are available in online supplemen-
tary file S1.
STATISTICAL ANALYSIS
Data were curated in Microsoft Excel. Fisher’s exact test and 
non- parametric Mann- Whitney U test, following D’Agostino and 
Pearson normality assessment, and curve fitting were conducted 
using GraphPad Prism V.6.07. Where immunoglobulin level 
was undetectable, the lower limit of detection (IgG 1.34 g/L; 
IgA 0.05 g/L and IgM 0.05 g/L) was used for data analysis, with 
density estimation and plotting performed in R (V.3.4.0). A two- 
tailed significance level of p<0.05 was used.
RESULTS
Enrichment of clozapine- treated patients within schizophrenia 
cases referred for immunology assessment and requiring immu-
noglobulin replacement therapy.
During the evaluation period, 1791 adults were assessed 
at ICW; 23 had a diagnosis of schizophrenia or schizoaffec-
tive disorders. We hypothesised that if clozapine- associated 
hypogammaglobulinaemia was clinically relevant, this would 
manifest in referral patterns. The mean clozapine prescrip-
tion (online supplementary table 1) rate reported by the 2014 
UK National Audit of Schizophrenia was 30%.17 We therefore 
expected a ratio of 7 clozapine:16 non- clozapine users. In 
contrast, we observed 17 patients with a history of clozapine 
use, corresponding to an OR of 6.48 (95% CI: 1.79 to 23.5), 
p=0.0072. This remained significant for prevalence estimates of 
clozapine use among the Welsh schizophrenia population up to 
43% (online supplementary file S2). Patients receiving clozapine 
accounted for 6/7 (86%) of schizophrenia cases requiring immu-
noglobulin replacement therapy (IgRT), approximately 3% of 
our adult IgRT cohort. This compares with the international 
schizophrenia prevalence of 0.4%–1%.18 19 This suggests enrich-
ment of clozapine- treated patients within our immunodeficiency 
cohort relative to the general population.
We next explored indication for referral and immuno-
logical finding at first assessment (individual patient details 
summarised—online supplementary file S1). Two clozapine- 
treatment patient with hypogammaglobulinaemia have been 
previously identified and reported.12 Recurrent infection was 
documented in 10/17 subjects (59%), predominately reflecting 
sinopulmonary infections. Four patients (24%) were referred 
with serum antibody levels below the fifth percentile without 
any antibiotic use in the preceding 12 months (summarised—
table 1). A low calculated globulin (CG) (<23 g/L) was present in 
15/17 (88%) of subjects receiving clozapine and was associated 
with reductions in IgG, IgA and IgM below the fifth percentiles in 
14/17 subjects. We also found referral rates increased following 
the national introduction of CG screening to Wales during 2014, 
and prior to release of our initial report12 (online supplemen-
tary file S3). Consistent with CG reduction, serum immunoglob-
ulin levels were also reduced (summarised in figure 1). Taken 
together, this is consistent with a clozapine- specific association 
with dysgammaglobulinaemia, and the utility of CG screening to 
stratify patients for specialist immunology assessment.
See online supplementary file S1 for individual patient values.
B-cell dysregulation associated with long-term clozapine use 
resembles CVID
Clozapine users are closely monitored for side effects of neutro-
paenia and agranulocytosis, and all individuals showed normal 
neutrophil counts at first assessment. Lymphopaenia and reduc-
tion in T cells were present but largely confined to two individ-
uals subsequently diagnosed with haematological malignancies 
(table 1; online supplementary file S2). Because the mechanisms 
underlying clozapine- associated hypogammaglobulinaemia 
remain unknown, we focused on B- cell clinical immunopheno-
typing data performed in isolation or as part of a full EUROClass 
evaluation.16 We took advantage of existing laboratory data to 
identify age- matched individuals with CVID (n=26) and healthy 
controls (n=16) to clozapine- treated patients (following exclu-
sion of cases with haematological malignancy, n=15). Clozapine- 
treated individuals showed normal total and naive B- cell counts 
(Figure 2A) but reduction of class- switched memory B cells 
(CSMB) relative to healthy individuals (Mann- Whitney U test, 
p<0.0001), with the exception of a single patient who had 
discontinued clozapine after a 2- month trial and had normal 
immunoglobulin levels (figure 2B; online supplementary file S2). 
Table 1 Immunology assessment summary at initial clinical visit
Schizophrenia with 
history of clozapine 
use
(median, range)
Adult reference range
(5th–95th percentile 
unless indicated*)
Number 17
Age, years (median, range) 50 (36–63)
Gender (M:F) 11:6
Neutrophils (median, range) 4.3 (2.0–10.2) 1.7–7.5×109/ L
Lymphocytes (median, range) 1.3 (0.8–2.1) 1.0–4.5×109/L
IgG 3.20 (1.20–6.65) 6.00–16.0 g/L
IgA 0.26 (0.05–0.81) 0.80–4.00 g/L
IgM 0.17 (0.05–0.64) 0.50–2.00 g/L
CD3+ T cells 930 (380–1960) 800–2500×106/ L
CD3+CD4+ T helper cells 600 (110–1350) 400–1500×106/ L
CD3+CD8+ cytotoxic T cells 230 (60–560) 200–1100×106/ L
CD19+ B cells 260 (100–450) 50–500×106/ L
CD56+ natural killer cells 90 (20–460) 80–650×106/ L
Naïve B cells (%B) (n=14) 83.8 (23.6–95.8) 58%–79.6%*
Marginal zone- like B cells (%B) 
(n=14)
11.0 (3.1–71.2) 7.4%–21.4%*
Class- switched memory B cells 
(%B) (n=16)
1.6 (0.2–11.6) 7.2%–18.9%*
Plasmablasts (%B) (n=6) 0.01 (0–0.04) 0.4–3.6*
Reference ranges for immunoglobulins47and lymphocyte subsets48 represent 
5th–95th percentiles.
*B cell adult reference ranges represent interquartile range (adapted from Morbach 
et al49). See also online supplementary table 1 for individual values.
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Immunophenotyping of plasmablasts was available for six indi-
viduals receiving clozapine and was comparable to CVID (Figure 
2C), but significantly reduced compared with age- matched 
healthy controls (Mann- Whitney U test, p=0.004). We observed 
a general decline in CSMB with increasing duration of clozapine 
therapy (figure 2D), which appears independent of age (online 
supplementary file S4).
Vaccine- specific IgG responses are routinely evaluated as 
part of clinical assessment.20 At initial assessment, levels below 
putative protective thresholds were common with IgG to H. 
influenzae B (HiB) <1 μg/mL21 in 12/16 assessed (75%); Pneu-
mococcal- IgG <50 mg/L22 in 15/16 (94%) and tetanus- IgG 
<0.1 IU/mL in 6/16 (38%) individuals tested. Post- Menitorix 
(HiB/MenC conjugated to tetanus toxoid) vaccination serology 
was assessed after 4 weeks, with 5/11 (45%) individuals failing to 
mount a HiB- IgG response ≥1 μg/mL, and 1/12 failing to exceed 
the ≥0.10 IU/mL postvaccination tetanus- IgG level defined by 
WHO.23 Following Pneumovax II, 6/16 (38%) individuals failed 
to develop an IgG response above a threshold of ≥50 mg/L22 (see 
online supplementary file S1 and online supplementary file S5 
for vaccine response assessment).
Reduction in infection burden following immunoglobulin 
replacement therapy
Our approach to antibody deficiency follows the previously 
reported findings.15 20 Cumulative follow- up for clozapine- 
associated hypogammaglobulinaemia now exceeds 61 patient- 
years (range 0.5–11 years), during which time 6/16 (38%) of 
clozapine- treated patients were commenced on IgRT. Over a 
12- month period prior to replacement, these patients received a 
mean of 6.5 acute antibiotic courses (range 3–12, including one 
inpatient admission requiring parenteral therapy). Following 
IgRT, this fell to a median of 1.5 oral antibiotics courses per 
year (range 0–2 courses), with no infection- triggered hospital 
admissions. Replacement through IgG levels ranged from 5.5 to 
9.6 g/L (mean 8.0 g/L).
Partial recovery of immunoglobulin following clozapine 
discontinuation
One patient (online supplementary table S1: IDs #7) discon-
tinued clozapine due to the known side effect of neutropaenia, 
detected by the clozapine monitoring programme, providing a 
unique opportunity to examine reversibility of humoral dysreg-
ulation. In the absence of IgRT, patient #7 has demonstrated a 
gradual recovery in terms of serum IgG level from 3.5 to 5.95 
g/L over 3 years, however IgA and IgM levels have remained 
depressed (figure 3). Patient #2 discontinued clozapine 2 years 
ago, having already commenced IgRT, with subsequent recovery 
of IgM from 0.22 to 0.86. IgA levels have remained below 
0.24 g/L. Together, this provides support for reversibility in 
humoral function following clozapine- withdrawal, but suggests 
this process is gradual and limited. In contrast, clozapine cessa-
tion in patient #2 was associated with profound and acute 
relapse of psychiatric symptoms, requiring prolonged inpatient 
admission to a specialist mental health unit.
DISCUSSION
In this retrospective review of referrals to a national immu-
nology centre, we found that individuals with schizophrenia 
receiving clozapine displayed clinically significant pan- 
hypogammaglobulinaemia, impaired vaccine responses and 
disturbed B- cell maturation with a proportion benefitting 
from IgRT. Consistent with a specific relationship to clozapine 
Figure 1 Immunoglobulin distribution in referred relative to referral cohort populations. Density plot showing distribution of serum immunoglobulin 
levels in patients receiving clozapine referred for immunology assessment (light blue, n=13 following removal of 4 patients, n=2 due to 
haematological malignancy and n=2 previously included within the case- control study). Comparison is made relative to the normal laboratory 
range (dotted lines, indicating 5th–95th percentiles) with comparison to immunoglobulin distributions in disease- control patient populations 
receiving clozapine (green, n=94) or alternative antipsychotic agents (pink, n=98) and following exclusion of individuals with alternative causes of 
hypogammaglobulinaemia.12
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use, we observed enrichment of clozapine use among patients 
with schizophrenia undergoing immunology assessment or 
requiring IgRT relative to that reported in the wider popula-
tion by a number of recent studies.4 17 24 The most common 
feature at referral was a low CG.25 Importantly, both clozapine 
and non- clozapine antipsychotic medications require routine 
liver function monitoring,26 arguing against a referral bias due 
to differential testing. While the use of CG screening is being 
developed in a number of countries, a lack of wider availability 
may limit the identification of antibody- deficient patients taking 
clozapine in other settings.25 27 28
Our finding of a temporal association between clozapine use 
and reduction in CSMB is consistent with our previous analysis 
of a separate cohort that hypogammaglobulinaemia appears a 
late manifestation of clozapine therapy.12 Our immunological 
findings associated with clozapine- associated hypogammaglob-
ulinaemia is independently supported by a recently reported 
peripheral blood immune signature for patients with TRS 
revealing reduced plasmablasts and CSMB relative to disease 
and healthy controls.29 While this study focused on psychiatric 
status, the majority of such patients were clozapine- treated; 
immunoglobulin levels were not determined by this group.29 
These findings also suggest that many clozapine- treated patients 
in our cohort and beyond may have received a diagnosis of 
CVID, according to internationally accepted criteria.30 We 
are conducting a wider survey of UK Immunology centres to 
examine this observation.
This study has several limitations, including its sample size 
and single- centre retrospective design. Prospective studies 
are required, for instance, to validate the association between 
therapy duration and effect on B- cell phenotypes, and to address 
causality. We speculate an effect targeting late- stage B- cell differ-
entiation or survival may underlie the observed findings.31 
However, at present, we cannot exclude a link to the underlying 
pathophysiology of schizophrenia, which like CVID remains 
largely unknown. Intriguingly, pathway analysis of schizophrenia 
associations have demonstrated marked enrichment at enhancers 
active in immune tissues, particularly B- lymphocyte lineages.32 
Polypharmacy, multimorbidity and socioeconomic status are 
common and important factors complicating healthcare delivery 
in schizophrenia33 34 and might also contribute to the observed 
findings. Smoking is common in both clozapine- treated and 
clozapine- naïve patients with schizophreniapatients,35 predis-
poses to pneumonia36 and may lead to systemic steroid therapy 
for chronic obstructive pulmonary disorder. However, the 
reduced CSMB and pan- hypogammaglobulinaemia profiles we 
observed clearly differ from the patterns previously reported 
with both steroids or smoking.37 38 Other medication including 
metformin and antiepileptics have been described to have 
immunomodulatory effects in murine studies39 or case series40; 
however, do not fully explain the observed hypogammaglobu-
linaemia—in line with the rigorous exclusion criteria applied 
during our initial case- control study.12 The immunomodula-
tory effects of the dibenzodiazepine clozapine are increasingly 
recognised beyond agranulocytosis and neutropaenia.41–43 Here, 
Figure 2 B- cell subsets in patients with schizophrenia with 
history of clozapine therapy (numbers as shown), common variable 
immunodeficiency (CVID, n=26) and healthy controls (n=17). B- 
cell subsets gated on CD19+ cells and defined as follows: (A) 
naïve B cells (CD27−IgD+IgM+); (B) class- switched memory B cells 
(CSMB, CD27+IgD−IgM−); (C) plasmablasts (CD19+CD27hiIgD-);. 
Non- parametric Mann- Whitney U test performed for non- normally 
distributed data, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; (D) 
relationship of clozapine therapy (data available for n=12) and CSMB 
(%). Line of best fit shown represents single- phase exponential decay 
modelling for this relationship, r2=0.649. ns, not significant.
Figure 3 Gradual recovery of serum IgG postdiscontinuation of 
clozapine in a single patient without recourse to immunoglobulin 
replacement. LLN, lower limit of normal (see online supplementary S1, 
patient #7).
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we present evidence of gradual recovery of humoral immune 
function following clozapine withdrawal in the absence of IgRT.
From a practical standpoint, recovery of immunoglobulin 
levels appeared gradual and variable. Weighed against the florid 
relapse in psychiatric symptoms observed following clozapine 
discontinuation in one, we do not currently suggest discontinua-
tion of clozapine in patients. This is in line with the unique effi-
cacy of clozapine in TRS,44 and availability of treatment options 
to mitigate the risks associated with antibody deficiency. Finally, 
given evidence of increased risk of pneumonia within individuals 
with schizophrenia7 45 46, our finding of low levels of baseline 
immunity to common vaccinations within this patient group 
highlights a simple strategy for risk mitigation.
Summary
We report the clinical features of clozapine- associated immu-
nodeficiency identified following the introduction of CG 
screening in Wales and highlight clinically significant pan- 
hypogammaglobulinemia, impaired vaccine responses and new 
findings of disturbed B- cell maturation. In support of a drug- 
related effect, we show a temporal association between clozapine 
exposure and reduction in CSMB levels, and evidence of gradual 
reversibility following discontinuation. Clinicians should be alert 
for this diagnostic overlap with CVID. Patients may benefit from 
monitoring or clinical intervention in the form of vaccination, 
antibiotic prophylaxis or IgRT. Clozapine’s immunomodulatory 
effects are poorly understood, and further studies are required 
to delineate mechanism.
Kudos plain language summary
The introduction of clozapine in the 1950s was a major thera-
peutic advance in the treatment of schizophrenia. It remains the 
gold standard therapy for approximately 3/10 individuals who fail 
to respond to initial management. Overall, clozapine improves 
symptoms and saves lives. Recent studies (2018) have suggested 
that clozapine therapy may be associated with a block in antibody 
production (causing antibody deficiency). This would predict 
patients receiving this therapy to be more likely to experience 
infections (such as pneumonia). This work examines patients 
referred to a major immunology centre since 2005, with focus 
on those receiving antipsychotic medicines (including clozapine). 
As predicted by the authors (but against the normal pattern of 
prescribing), clozapine was the most common antipsychotic used 
by patients referred with antibody deficiency. The authors go on 
to define the clinical and immunological features of this group, 
highlighting a close similarity to individuals without a known 
cause of antibody deficiency. Several clozapine- treated patients 
went on to receive antibody replacement therapy, successfully 
reducing their infection rate. By following these patients over 
time, they also saw that in one patient who stopped clozapine 
treatment this was associated with a gradual return in their 
major antibody (IgG). This adds support to the argument that 
clozapine therapy is associated with a drug- related (secondary) 
antibody deficiency. This is an important finding for immunolo-
gists around the work, who could easily confuse a drug- related 
cause of antibody deficiency with an inherited (primary) case. 
The authors remain cautious and suggest further studies are 
needed with greater size and following patients before and after 
they start/stop clozapine. This is because the disease processes 
underlying both schizophrenia and primary antibody deficiency 
remain largely unknown: meaning there could be important 
shared mechanisms linking both conditions.
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